Home
Diseases
Melanoma
Clinical Trials

Clinical Trials Related to Melanoma

Related studies linked through entity extraction aliases.

A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)

Status: COMPLETED
Phase: PHASE2

A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)

Status: COMPLETED
Phase: PHASE2

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Status: TERMINATED
Phase: PHASE1/PHASE2

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Fluorescence Surgery for Sentinel Node Identification in Melanoma

Status: UNKNOWN
Phase: NA

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Status: COMPLETED
Phase: PHASE1

A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)

Status: COMPLETED
Phase: PHASE1/PHASE2

A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma

Status: COMPLETED
Phase: PHASE2

Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children

Status: COMPLETED
Phase: NA

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Status: COMPLETED
Phase: PHASE1/PHASE2

GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases

Status: COMPLETED
Phase: PHASE2

Validation of MMS Test for Cancer Monitoring

Status: TERMINATED
Phase: N/A

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

Status: COMPLETED
Phase: PHASE1

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Status: TERMINATED
Phase: PHASE2

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive

Status: COMPLETED
Phase: PHASE1/PHASE2

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Status: COMPLETED
Phase: PHASE1

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

Status: COMPLETED
Phase: PHASE1

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

Status: UNKNOWN
Phase: NA

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

Status: COMPLETED
Phase: PHASE2

Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)

Status: COMPLETED
Phase: PHASE1/PHASE2